Search for...

The Greek AI platform Intelligencia raises $12M to de-risk drug development

A woman holding a bottle of pills drug development
Image credit: Pexels
, ~

Intelligencia, the AI software platform that helps pharmaceutical and biotechnology companies reduce drug development risks and introduce new drugs to market faster, raised $12M In a Series A round led by the European health tech investor MTIP. Two of the previous seed-round investors, the Greek Big Pi Ventures and Synetro Group, also participated and were joined by the international analytics biopharmaceutical company ZS. 

The round will be used for product development and the expansion of its Greek R&D team, for an increase in sales and expansion of its customer success teams. The startup will also aim to develop new partnerships with clients and partners to incorporate more data in its algorithms. 

As the success rates of clinical drug development which historically has been around 10% are falling, and the average expenses of bringing a new drug to market are estimated at $2.6B, it is getting increasingly difficult and costly for pharmaceutical companies to provide patients with new drugs. This is where Intelligencia comes to fill in the market gaps. With the mission to bring innovative therapies to patients faster and with reduced risk, the company offers drug development companies ML-fueled predictions about the trials they conduct to aid their critical decision-making process.

 Assess, quantify and reduce the risk of drug development

The Greek founders of Intelligencia, Dimitrios Skaltsas and Vangelis Vergetis, have a longtime background in healthcare consulting. They worked for McKinsey & Company previous to founding their company in 2017. For its four years on the market, the company has created a team of 40 software engineers, AI specialists, scientists, and drug development practitioners which are dispersed between the New York headquarters and the R&D center in Athens, Greece.  

Unlike other tech startups in the pharmaceutical field that aim to enable pharmaceutical companies to search for drugs with their own AI, Intelligencia partners with pharmaceutical companies to provide them with software that can reduce the chances of failure in drug development and clinical trials. By using AI to predict the result of a particular clinical trial, it makes recommendations on how to improve them, and suggests other relevant areas for research to explore. To offer accurate predictions and analysis the proprietary algorithms of the platform assess more than 1.5B data points across clinical trial design, clinical outcomes, drug biology, funding, regulatory pathways, patients, and medical publications. 

Read more:  The Greek “Alexa” of molecular diagnostics closes a €1.45М seed round  

Basically, it de-risks the drug development process. Besides estimating the risk of failure, the platform analyses the factors that hinder the success of the trial. The main value proposition of the company is that its data-driven methodology is able to accurately assess risk both across internal development programs and across external business development programs and partnerships. 

Vangelis Vergetis refers to the movie “Moneyball” with Brad Pitt who uses data to build a winning baseball team to explain how his team brings innovation in the healthcare industry. “In a similar way, we combine carefully curated data (biological, clinical, genomic, etc.) together with AI in order to revolutionize how drug developers think about and assess the risk of their pipelines and specific development programs,” he says.  


Thank you for reading The Recursive!

Over 1 million people from all over the world have learned about the tech ecosystem in Central and Eastern Europe thanks to The Recursive. In order to keep our content free for everyone, we need your help. If you believe what we do is important and have the means to do so, support us in giving a voice to Central and Eastern Europe with as little as €7. Thank you!

DONATE Keep reading this article

Help us grow the emerging innovation hubs in Central and Eastern Europe

Every single contribution of yours helps us guarantee our independence and sustainable future. With your financial support, we can keep on providing constructive reporting on the developments in the region, give even more global visibility to our ecosystem, and educate the next generation of innovation journalists and content creators.

Find out more about how your donation could help us shape the story of the CEE entrepreneurial ecosystem!

One-time donation

You can also support The Recursive’s mission with a pick-any-amount, one-time donation. 👍

Elena is an Innovation Reporter at The Recursive, an online media dedicated to the emerging tech and startup ecosystems in Southeast Europe. She is keen on sharing the innovation stories that shape the regional ecosystem and has a great interest in fintech, IoT, and biotech startups. Elena is currently finishing her Bachelor's Degree in Business Administration and Political Science at the American University in Bulgaria.